SecProbe.io

CORRESP
1
filename1.htm

Cytomedix, Inc.

209 Perry Parkway, Suite 7, Gaithersburg,
MD 20877

November 6, 2012

Division of Corporation Finance

U.S. Securities & Exchange Commission

100 F Street, NE

Washington, D.C. 20549

    Attn:
    Mary Beth Breslin, Esquire

    Senior Attorney

    Re:
    Cytomedix, Inc.

    Registration Statement on Form S-3 (File No. 333-183704)

Dear Ms. Breslin:

Pursuant to Rule 461
of the Securities Act of 1933, as amended (the “Securities Act”), Cytomedix, Inc. (the “Company”), respectfully
requests that the effective date of its Registration Statement on Form S-3 (File No. 333-183704) (“Registration Statement”)
be accelerated and that such Registration Statement become effective at 4:30 P.M., Washington, D.C. time, on Thursday, November
8, 2012, or as soon thereafter as practicable.

Furthermore, the Company
acknowledges the following:

 · should the Securities and Exchange Commission (“Commission”) or the staff, acting pursuant
to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action
with respect to the Registration Statement;

 · the action of the Commission or the staff, acting pursuant to delegated authority in declaring
the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of
the disclosure in the Registration Statement; and

 · the Company may not assert staff comments and the declaration of effectiveness of the Registration
Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United
States.

    Very truly yours,

    CYTOMEDIX, INC.

    /s/ Andrew Maslan

    Name:  Andrew Maslan

    Title:    Chief Financial Officer